Ex vivo therapeutic index by drug sensitivity using fresh human normal and tumor cells

Journal of Experimental Therapeutics and Oncology

Volumn 4, Issue 2, 2004, Pages 145-154

  Bosanquet, Andrew G ^a   Bell, Philip B ^a  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

Apoptosis by Morphology assay; Efficacy; Ex vivo drug sensitivity assay; Therapeutic index; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MAFOSFAMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CHILD; CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MORPHOLOGY; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; THERAPEUTIC INDEX; TUMOR CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MIDDLE AGED; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 4043131643     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Frei E, III,Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res 4:2027-2037, 1998.
2. Hellman S. Improving the therapeutic index in breast cancer treatment: the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 40:4335-4342, 1980.
3. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293-1302, 2002.
4. Webb DK. Management of relapsed acute myeloid leukaemia. Br J Haematol 106:851-859, 1999.
5. Maehara Y, Kusumoto H, Kusumoto T, Anai H, Sugimachi K. Tumor tissue is more sensitive to mitomycin C, carboquone, and aclacinomycin A than is adjacent normal tissue in vitro. J Surg Oncol 40:4-7, 1989.
6. Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D, Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol 9:357-364, 1998.
7. Bosanquet AG, Bell PB. Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leuk Res 20:143-153, 1996.
8. Bosanquet AG, Forskitt S. Effect of cell isolation methods and drug concentration on the use of the Differential Staining Cytotoxicity (DiSC) assay with solid tumours. Cytotechnology 2:225-232, 1989.
9. Bird MC, Bosanquet AG, Gilby ED. In vitro determination of tumour chemosensitivity in haematological malignancies. Hematol Oncol 3:1-10, 1985.
10. Bird MC, Bosanquet AG, Forskitt S, Gilby ED. Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in vitro chemosensitivity of haematological malignancies. Leuk Res 10:445-449, 1986.
11. Bosanquet AG, Bosanquet MI. Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia. Leukemia 14:712-715, 2000.
12. Bosanquet AG, Burlton AR, Bell PB. Parameters affecting the ex vivo cytotoxic drug sensitivity of human haematopoietic cells. J Exp Ther Oncol 2:53-63, 2002.
13. Bosanquet AG, Bell PB. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood 87:1962-1971, 1996.
14. Kaspers GJ, Pieters R, Van Zantwijk CH, De Laat PA, De Waal FC, Van Wering ER et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64:469-474, 1991.
15. Tisman G, Herbert V, Edlis H. Determination of therapeutic index of drugs by in vitro sensitivity tests using human host and tumor cell suspensions. Cancer Chemother Rep 57:11-19, 1973.
16. Double JA, Bibby MC. Therapeutic index: a vital component in selection of anticancer agents for clinical trial. J Natl Cancer Inst 81:988-994, 1989.
17. Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RL et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 86:2849-2855, 1995.
18. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 91:1281-1287, 1999.
19. Looney WB, Hopkins HA. Rationale for different chemotherapeutic and radiation therapy strategies in cancer management. Cancer 67:1471-1483, 1991.
20. Brenner MK. Hematological malignancies. FASEB J 11:640-648, 1997.
21. Collins JM. Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans. Clin Cancer Res 6:1203-1204, 2000.
22. Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 5:4191-4198, 1999.
23. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 83:257-262, 2001.
24. Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care 15:173-184, 1999.
25. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol 106:71-77, 1999.
26. Catovsky D. Chronic Lymphocytic Leukaemia Trial 4. pp 1-40. 2001. Url: http://www.icr.ac.uk/haemcyto/CLL4/PDFs/CLL4_protocol_revised_27-2-2001.pdf. Accessed February 2004.